12-7-16/WED 10am: Jedd D. Wolchok, MD/PhD(Mem. Sloan Kettering) Lecture: "Combination Checkpoint Blockade" (free to public) Location: The Wistar Institute, Philadelphia (Jedd D. Wolchock: Chief of Melanoma & Immunotherapeutics Service, MSKCC) https://www.wistar.org/events/2016/12/combination-checkpoint-blockade
We don’t know if Dr. Wolchok will mention Peregrine/Bavi in his talk (North40000/Eb0783/Wook will let us know!), but RECALL that on 11-14-16, Dr. Wolchok’s MSKCC Lab Team, jointly with PPHM Scientists, presented a poster on Triple Combo Rad+Bavi+aPD1 vs. Melanoma: ...11-14-16: Dr. Jedd Wolchok states, “Based on these study results, we believe that the targeting of PS is having meaningful activity within the tumor microenvironment in the B16 melanoma model. It appears that this activity creates a more immune active environment in which other treatments, including radiation, are able to have a greater anti-tumor impact." See: http://tinyurl.com/js3fca4 5-29-15: Peregrine & Sloan Kettering Enter Collab. to “Investigate Novel PS-Targeting Immunotherapy Combos” http://tinyurl.com/o3k9ux8
= = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = Dec7/WED: WCLC’16 - IASLC’s 17th World Conf. on Lung Cancer, Vienna, Austria http://tinyurl.com/z8cq8vx …2:30-3:45pm UTSW’s Dr. David Gerber to present addl. Biomarker data from Ph3.SUNRISE Trial: “A Pre-Treatment Serum Test Based on Complement & IL-10 Pathways Identifies Patients Benefiting from the Addition of Bavituximab to Docetaxel”
Dec7/WED 10am: MSKCC’s Dr. Jedd Wolchok lecture at Wistar on “Combination Checkpoint Blockade"
Dec8/THU: 39th San Antonio Breast Cancer Symposium” http://tinyurl.com/zb5sopc ...Dr. Bruce Freimark(Dir.Res/Preclin.Oncology) poster: “PS-Targeting Enhances Anti-LAG3 in Murine Breast Cancer Tumors”
Market Data 
Markets 
AI
